Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study

被引:47
|
作者
Ninan, Jem [1 ]
Anh-Minh Nguyen [3 ]
Cole, Antonia [1 ]
Rischmueller, Maureen [1 ]
Dodd, Thomas [4 ]
Roberts-Thomson, Peter [5 ]
Hill, Catherine L. [1 ,2 ]
机构
[1] Queen Elizabeth Hosp, Rheumatol Unit, Woodville, SA 5011, Australia
[2] Univ Adelaide, Hlth Observ, Woodville, SA, Australia
[3] Dept Hlth, Hlth Stat Unit, Woodville, SA, Australia
[4] SA Pathol, Dept Tissue Pathol, Woodville, SA, Australia
[5] Flinders Med Ctr, Dept Allergy Immunol & Arthrit, Woodville, SA, Australia
关键词
MORTALITY RATE; GIANT CELL ARTERITIS; BIOPSY-PROVEN; TEMPORAL ARTERITIS; POLYMYALGIA-RHEUMATICA; SURVIVAL;
D O I
10.3899/jrheum.101254
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To compare mortality rates and cause of death in patients with biopsy-proven giant cell arteritis (GCA) with those in the general population. Methods. Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies in South Australia, from January 1, 1992, to December 31, 2006. All patients with biopsy-proven GCA were linked to the South Australian Births, Death and Marriage Registry to identify deaths until December 31, 2006. Standardized mortality ratios and relative survival (ratio of observed survival in GCA group to expected survival of general South Australian population, matched by age, sex, and calendar time) were calculated. The cause of death recorded on the death certificate was also documented. Results. There were 225 cases of biopsy-proven GCA (163 women and 62 men). The mean age at diagnosis of GCA was 78.2 years. The mean followup period was 66.2 months (SD 47.1 mo). During the followup period, there were 71 deaths in the GCA group (50 women, 21 men). The standardized mortality ratio was 0.99 (95% CI 0.77-1.25). The relative survival for different followup periods demonstrates that patients with GCA experienced similar mortality to the general population (age-matched and sex-matched). Death from cardiovascular causes (45%) was the most common, followed by infection (17%) and cancer (17%). Infection was a significantly more common cause of death in the first year (chi-squared, p = 0.0002). Conclusion. Our population-based cohort study did not demonstrate any increased mortality risk for patients diagnosed with biopsy-proven GCA. The risk of death from infection early in the disease may be increased. (First Release Aug 15 2011; J Rheumatol 2011;38:2215-17; doi:10.3899/jrheum.101254)
引用
收藏
页码:2215 / 2217
页数:3
相关论文
共 50 条
  • [41] The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis
    Lopez-Diaz, Maria J.
    Llorca, Javier
    Gonzalez-Juanatey, Carlos
    Pena-Sagredo, Jose L.
    Martin, Javier
    Gonzalez-Gay, Miguel A.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2008, 38 (02) : 116 - 123
  • [42] Biopsy-Proven Giant Cell Arteritis Associated Vision Loss in Chinese Subjects: A Case Series and Review of the Literature
    Yan, Yan
    Li, Zhen
    Luo, Yuanyuan
    Chen, Ping
    Liu, Lin
    NEURO-OPHTHALMOLOGY, 2023, 47 (02) : 79 - 87
  • [43] Association between IL-18gene polymorphisms and biopsy-proven giant cell arteritis
    Rogelio J Palomino-Morales
    Tomas R Vazquez-Rodriguez
    Orlando Torres
    Inmaculada C Morado
    Santos Castañeda
    Jose A Miranda-Filloy
    Jose L Callejas-Rubio
    Benjamin Fernandez-Gutierrez
    Miguel A Gonzalez-Gay
    Javier Martin
    Arthritis Research & Therapy, 12
  • [44] Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study
    Restuccia, Giovanna
    Boiardi, Luigi
    Cavazza, Alberto
    Catanoso, Mariagrazia
    Macchioni, Pierluigi
    Muratore, Francesco
    Soriano, Alessandra
    Cimino, Luca
    Aldigeri, Raffaella
    Crescentini, Filippo
    Pipitone, Nicolo
    Salvarani, Carlo
    JOURNAL OF AUTOIMMUNITY, 2017, 77 : 39 - 44
  • [45] The use of intravenous methylprednisolone in giant cell arteritis: a population-based study
    Henningson, Hampus
    Hammar, Bjorn
    Mohammad, Aladdin J.
    RHEUMATOLOGY, 2024, : 2083 - 2090
  • [46] Association of CD24 gene Polymorphisms with susceptibility to biopsy-proven giant cell arteritis
    Rueda, Blanca
    Miranda-Filloy, Jose A.
    Martin, Javier
    Gonzalez-Gay, Miguel A.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (05) : 850 - 854
  • [47] Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden
    Stamatis, Pavlos
    Mohammad, Moman Aladdin
    Gisslander, Karl
    Merkel, Peter A.
    Englund, Martin
    Turesson, Carl
    Erlinge, David
    Mohammad, Aladdin J.
    RMD OPEN, 2024, 10 (02):
  • [48] All-cause and cause-specific mortality in patients with giant cell arteritis: a nationwide, population-based cohort study
    Therkildsen, Philip
    Nielsen, Berit Dalsgaard
    de Thurah, Annette
    Hansen, Ib Tonder
    Norgaard, Mette
    Hauge, Ellen-Margrethe
    RHEUMATOLOGY, 2022, 61 (03) : 1195 - 1203
  • [49] Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012
    Michet, Clement John, III
    Achenbach, Sara J.
    Crowson, Cynthia S.
    Matteson, Eric L.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 45 (01) : 70 - 74
  • [50] Absence of anti-β2 glycoprotein I antibodies in giant cell arteritis:: A study of 45 biopsy-proven cases
    Liozon, E
    Roussel, V
    Roblot, P
    Liozon, F
    Preud'homme, JL
    Loustaud, V
    Vidal, E
    Jauberteau, MO
    BRITISH JOURNAL OF RHEUMATOLOGY, 1998, 37 (10): : 1129 - 1131